Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02403284 · ClinicalTrials.gov registry record · Phase 4
The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
A Phase 4 study, sponsored by Phoenix VA Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
NCT02403284: Completed Phase 4 study, sponsored by Phoenix VA Health Care System.
NCT02403284 is a Phase 4 study that has completed, run by Phoenix VA Health Care System. The registered enrollment target is 97 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02403284, a Phase 4 study, has completed, sponsored by Phoenix VA Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
Study Summary
In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.
Primary Outcome
An insulin suppression test will be measured before and approximately 3 weeks after each treatment phase. Key time frames for assessing steady state plasma glucose will be between 150 and 180 minutes during the insulin suppression test
Interventions
- DRUG Liraglutide
- DRUG Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2013-03 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 4 |
What the finished NCT02403284 record still lists
NCT02403284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Liraglutide is the first listed.
NCT02403284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02403284 about?
NCT02403284 is a clinical study titled "The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans". In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.
What is the current status of trial NCT02403284?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2013-03. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT02403284?
The interventions under investigation include: Liraglutide (DRUG), Sugar Pill (DRUG).
Who is sponsoring clinical trial NCT02403284?
This trial is sponsored by Phoenix VA Health Care System, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02403284's enrollment target sits among peer trials
97 861st of 2000 higher than 1,138 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia